Do Braf(V600e) Mutation And Sodium-Iodide Symporter Expression Affect The Response To Radioactive Iodine Therapy In Patients With Papillary Thyroid Carcinoma?

ObjectiveTo report on the associations between BRAF(V600E) and sodium iodide symporter expressions and treatment outcomes in patients with papillary thyroid carcinoma.MethodsInclusion criteria included a pathologic diagnosis of papillary thyroid carcinoma of any stage, thyroidectomy followed by radioactive iodine therapy, and follow-up for at least 12 months after initial therapy. Events were classified as persistent or recurrent disease based on a clinical or investigational evidence of disease within or after, respectively, 1 year from initial therapy. Disease-free survival was calculated between the dates of surgery and confirmed event. Patients with no evidence of disease were censored at their last follow-up (censored group). BRAF(V600E) mutation and sodium-iodide symporter expressions were evaluated using immunohistochemistry.ResultsThe study included 78 patients (60 females, 18 males) with median age 36 years (range: 20-70 years). BRAF(V600E) was positive in 78%, equivocal in 13%, and negative in 9%. Sodium-iodide symporter was positive in 88%. BRAF(V600E) mutation was significantly associated with increasing tumor size, presence of lymphovascular invasion, classic subtype of papillary thyroid carcinoma, thyroid capsular infiltration, and lymph node metastasis. Sodium-iodide symporter expression was not associated with any clinical or pathologic characteristics. Patients with negative or equivocal BRAF(V600E) had significantly better disease-free survival (82%, 3 events) compared to the positive group (41%, 33 events; P=0.02).ConclusionIn patients with papillary thyroid carcinoma, BRAF(V600E) mutation is associated with high-risk pathological characteristics and worsened disease-free survival.